Opendata, web and dolomites

VALSL

Valorisation of splice-switching oligonucleotides for lung cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VALSL project word cloud

Explore the words cloud of the VALSL project. It provides you a very rough idea of what is the project "VALSL" about.

route    mechanisms    functions    optimization    tumour    reagents    messenger    tumours    gene    disease    plethora    off    inhibit    context    administered    displaying    healthcare    regulation    critical    alone    mechanism    antagonistic    antisense    efficient    experimental    funds    company    combination    goals    single    market    added    lung    successful    translate    poc    intellectual    lack    chemotherapy    society    alterations    property    adenocarcinoma    molecular    here    protection    preclinical    fundamental    stakeholders    vitro    mascp    prognosis    pathologies    proteins    aligned    therapeutic    variety    rnas    cell    innovation    assets    repress    ranging    class    proliferation    intranasally    erc    therapies    recruitment    gap    incidence    mice    xenografts    venture    mouse    dose    modulate    requests    roles    mechanistic    models    plays    oligonucleotides    alternative    modifying    capital    bridge    splicing    linked    spin    treatments    neurodegenerative    cancer    patient    poor   

Project "VALSL" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO CENTRE DE REGULACIO GENOMICA 

Organization address
address: CARRER DOCTOR AIGUADER 88
city: BARCELONA
postcode: 8003
website: www.crg.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 149˙894 €
 EC max contribution 149˙894 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO CENTRE DE REGULACIO GENOMICA ES (BARCELONA) coordinator 149˙894.00

Map

 Project objective

Here we propose to test the therapeutic potential of a novel class of reagents, known as splicing-modifying antisense oligonucleotides, in preclinical models of lung adenocarcinoma, including patient-derived tumours in mice. Alternative splicing is a major mechanism of gene regulation by which different messenger RNAs and proteins are generated from a single gene, often displaying distinct, even antagonistic functions. Alterations in alternative splicing have been linked with a plethora of pathologies ranging from neurodegenerative disease to cancer. As a result of detailed mechanistic analyses of alternative splicing regulation in the context of the ERC-funded MASCP project, we have identified antisense oligonucleotides that modulate alternative splicing of a gene that plays key roles in the control of lung cancer cell proliferation. These reagents repress cell growth in vitro as well as inhibit tumour growth when administered intranasally in mouse models of lung adenocarcinoma. The main experimental goal of the ERC PoC proposal is to test the therapeutic value of the antisense oligonucleotides in a variety of patient-derived xenografts in mice, alone or in combination with other treatments, including chemotherapy. This will require previous optimization of dose and delivery route, which is being carried out with available support from other healthcare innovation funds. These goals are aligned with requests from various stakeholders, and funding from the ERC PoC program will be critical for successful valorisation of our assets, intellectual property protection and recruitment of venture capital to establish a spin-off company. Given the high incidence, poor prognosis and lack of efficient therapies for lung cancer, the work proposed can translate fundamental knowledge on molecular mechanisms of gene regulation derived from the ERC-funded MASCP project into applications whose valorisation can bridge the gap to market and provide added value for society.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VALSL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VALSL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

THERMONANO (2018)

Nanoassemblies for the subcutaneous self-administration of anticancer drugs

Read More  

HyperCube (2020)

HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields

Read More  

RESOURCE Q (2019)

Efficient Conversion of Quantum Information Resources

Read More